ONA-418

ONA-418 is a preclinical-stage dual-payload antibody-drug conjugate (ADC) being developed by ONA Therapeutics for the treatment of prevalent solid tumors. As a dual-payload ADC, the molecule is engineered to deliver two distinct cytotoxic agents to the target cell, a strategy intended to enhance therapeutic efficacy and potentially overcome drug resistance mechanisms associated with single-payload ADCs. While the specific molecular target and the chemical nature of the payloads remain undisclosed by the developer, the program is positioned to address high-prevalence solid malignancies. ONA Therapeutics focuses on the biology of tumor-initiating cells and metastasis, and ONA-418 represents a key asset in their next-generation ADC pipeline.